Home›Stock Screener›Eris Lifesciences

Eris Lifesciences Share Price Today | Stock Price & Eris Lifesciences Share Screener

ERIS Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1329.00
▼ -8.10 (-0.61%)
2026-11-19 00:00:00
Live Share Price BSE
₹1327.90
▼ -11.80 (-0.88%)
2026-11-19 00:00:00

As of November 19, 2026, the live Eris Lifesciences share price (NSE: ERIS) is ₹1,329.00 on NSE and ₹1,327.90 on BSE, down 0.61% from the previous close, with shares trading between ₹1,315.10 and ₹1,344.70 in today's trading session, and a 52-week range of ₹1,095.50–₹1,701.30. Track ERIS market capitalization to gauge the company's total market size. Use the Eris Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Eris Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹893 and net income of ₹187, with EBITDA of ₹273, an operating margin of 30.0% and a profit margin of 20.9%.

Eris Lifesciences Market Cap ₹18,848.72 Cr.
ERIS P/E Ratio (TTM) 25.60
Eris Lifesciences P/B Ratio 4.44
EPS (TTM) ₹45.33
Dividend Yield 0.54%
Debt to Equity 0.72
ERIS 52 Week High ₹1701.30
Eris Lifesciences 52 Week Low ₹1095.50
Operating Margin 30.00%
Profit Margin 20.94%
ERIS Revenue (TTM) ₹893.00
EBITDA ₹273.00
Net Income ₹187.00
Total Assets ₹7,366.00
Total Equity ₹3,896.00

Eris Lifesciences Share Price Chart

Track the current stock price of Eris Lifesciences with an interactive chart. Analyse ERIS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Eris Lifesciences stock quote in one place.

The quote of ₹1,329.00 sits between the 52-week low of ₹1,095.50 and the 52-week high of ₹1,701.30, and the latest session moved -0.61% from the previous close.

Eris Lifesciences Company Profile - Fundamental Screener

Screen Eris Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ERIS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Amit Indubhushan Bakshi listed as chairperson or CEO, and it trades under ISIN INE406M01024.

Business Overview

Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Amit Indubhushan Bakshi
ISIN INE406M01024

Eris Lifesciences Balance Sheet Screener

Screen ERIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹7,366, up from ₹7,036 in 2025.

Latest statistics put total assets at ₹7,366 and shareholder funds at ₹3,896, with a leverage ratio of 0.72.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 7,366 7,036 7,041 3,667 2,272 1,835 1,552 1,554 1,460 727
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 5,188 5,307 4,319 2,568 918 854 875 761 771 232

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 1,393 2,380 1,286 1,003 164 91 91 79 349 60
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 3,896 3,272 3,222 2,221 1,908 1,576 1,296 1,169 886 591
Share Capital 14 14 14 14 14 14 14 14 14 14
Reserves & Surplus 3,889 2,841 2,573 2,182 1,894 1,563 1,283 1,137 848 553

Eris Lifesciences Income Statement Screener - Profit & Revenue Analysis

Screen Eris Lifesciences income statement and profit fundamentals. Analyze ERIS quarterly results. Eris Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹893 and net profit was ₹187, equal to earnings per unit of ₹13.26, at an operating margin of 30%.

In that period expenses were ₹620, interest cost ₹46 and tax ₹-31. The next period listed, 2026-Jun, shows revenue of ₹871 and net profit of ₹143.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 893 871 755 801 793 775 711 726 744 717 562 488 504 461 398
Expenses 620 577 484 543 504 496 453 477 477 470 403 311 324 297 284

Operating Costs and Margins

EBITDA 273 294 270 258 289 279 258 249 267 248 160 177 180 164 114
Operating Profit % 30.00% 34.00% 36.00% 32.00% 36.00% 36.00% 36.00% 34.00% 35.00% 34.00% 26.00% 36.00% 35.00% 35.00% 28.00%
Depreciation 73 72 70 70 69 71 77 81 81 76 54 46 42 41 35
Interest 46 47 46 49 50 49 54 57 60 60 33 18 16 17 9

Profit and Earnings

Profit Before Tax 156 180 159 145 173 161 129 116 129 116 77 116 126 113 76
Tax -31 36 -120 37 38 36 27 29 33 26 -3 14 4 19 14
Net Profit 187 143 279 109 135 125 102 87 96 90 80 102 122 94 62
EPS 13.26 10.28 20.60 7.32 8.82 8.66 6.90 6.16 6.73 6.11 5.22 7.55 9.08 6.97 4.81

Eris Lifesciences Cash Flow Screener - Liquidity Fundamentals

Screen ERIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹538, and net cash flow was an outflow of ₹145.

Over the same period, investing activities used ₹370 and financing activities used ₹314.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 538 1,065 486 292 378 375 271 223 235 200
Investing Activities -370 -78 -1,828 -975 -320 -323 123 -5 -590 -185

Financing and Net Cash

Financing Activities -314 -881 1,380 688 -45 -82 -335 -221 363 -24
Net Cash Flow -145 106 38 5 14 -30 60 -3 8 -8

Eris Lifesciences Shareholding Pattern Screener

See Eris Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check Eris Lifesciences promoter holding and ownership changes for ERIS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 53.92%, foreign institutions 6.39%, domestic institutions 20.35% and the public 10.06%, spread across 51,656 shareholders.

The shareholder count was 51,656 in 2026-Mar, compared with 50,798 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 53.92% 54.14% 54.74% 54.85% 54.83% 54.85% 54.85% 54.90%

Institutional Investors

FII Holding 6.39% 5.75% 5.74% 8.43% 8.40% 7.21% 6.85% 14.27%
DII Holding 20.35% 20.72% 20.20% 18.07% 18.17% 19.36% 20.32% 15.63%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 10.06% 10.10% 9.94% 9.16% 9.12% 9.12% 8.51% 14.24%
Other Holding 9.26% 9.29% 9.38% 9.49% 9.47% 9.45% 9.48% 0.95%
Shareholder Count 51,656 50,798 49,034 50,087 52,225 59,438 54,713 51,753

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Eris Lifesciences. Eris Lifesciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹7.21 per unit for 2026-March, a yield of 0.54%, compared with ₹7.35 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹7.21, ₹7.35 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹7.21 0.54%
2025-March ₹7.35 0.57%
2024-March ₹0.00 0.00%
2023-March ₹7.35 0.87%
2022-March ₹6.01 1.05%
2021-March ₹5.50 0.80%
2020-March ₹2.87 0.47%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Eris Lifesciences Stock Index Membership - Nifty & Sensex

See which indices include Eris Lifesciences stock. Check ERIS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 14 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP

Eris Lifesciences Market Events Screener - Corporate Actions

Get Eris Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Eris Lifesciences stock events that may affect ERIS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 26, 2026, with a record date of October 26, 2026.

It is followed by Annual General Meeting dated September 25, 2026 and Quarterly Result Announcement dated July 29, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-26 2026-10-26 Quarterly Result Announcement NA -4.27%
2026-09-25 2026-09-25 Annual General Meeting NA -3.23%
2026-07-29 2026-07-29 Quarterly Result Announcement NA -3.46%
2026-05-29 2026-05-29 Dividend ₹ 7.21 /share 1.09%
2026-05-20 2026-05-20 Quarterly Result Announcement NA -2.81%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 6.90%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -0.28%
2025-08-05 2025-08-05 Quarterly Result Announcement NA 0.55%
2025-07-25 2025-07-25 Annual General Meeting NA 6.29%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 4.50%
2025-02-13 2025-02-13 Dividend ₹ 7.35 /share -10.84%
2025-02-04 2025-02-04 Quarterly Result Announcement NA 7.93%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -3.41%
2024-09-25 2024-09-25 Annual General Meeting NA -9.82%
2022-08-11 2022-08-16 Dividend ₹ 7.35 /share -0.23%

Eris Lifesciences Competitors Screener - Peer Stocks Comparison

Screen ERIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 449,923 40.80 61,674 12.69% 11,565 59.98
Divis Laboratories 297,258 87.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 176,426 85.00 13,886 20.34% 2,138 49.31
Laurus Labs 126,330 89.90 6,868 22.01% 890 49.19
Zydus Life Science 120,070 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,762 41.80 35,059 3.90% 4,158 69.34
Cipla 112,292 39.50 29,045 2.24% 3,870 55.82
Mankind Pharma 108,226 47.90 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,188 25.80 34,145 5.56% 3,503 60.38
Lupin 89,336 17.30 29,039 26.75% 5,356 44.23

Eris Lifesciences Company Announcements - News & Reports Screener

Screen ERIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 10, 2026 and November 4, 2026.

Date Update Actions
2026-11-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-04 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-10-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-29 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-10-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-26 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-26 Financial Results For Quarter And Half Year Ended September 30 2026 -
2026-10-26 Board Meeting Outcome for Outcome Of Board Meeting -
2026-10-19 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-19 Board Meeting Intimation For Consideration And Approval Of The Financial Results For The Period Ended September 30 2026 -
2026-10-19 Board Meeting Intimation for Consideration And Approval Of The Financial Results For The Period Ended June 30 2026 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-05 Announcement under Regulation 30 (LODR)-Resignation of Director -
2026-09-28 Closure of Trading Window -
2026-09-25 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-25 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-25 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-22 Announcement under Regulation 30 (LODR)-Allotment -
2026-09-21 Appointment Of Mr. Akhil Awasthi As An Additional Director (Non-Executive Independent) Of The Company -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,329.00, within a 52-week range of ₹1,095.50 to ₹1,701.30. The P/E ratio is 25.60 and the P/B ratio is 4.44, with earnings per unit of ₹45.33. Market capitalisation stands at ₹18,848.72 Cr and the dividend yield is 0.54%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.